Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2014

01-01-2014 | Preclinical study

CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis

Authors: Subir Biswas, Suman Sengupta, Sougata Roy Chowdhury, Samir Jana, Gunjan Mandal, Palash Kumar Mandal, Nipun Saha, Vivek Malhotra, Arnab Gupta, Dmitry V. Kuprash, Arindam Bhattacharyya

Published in: Breast Cancer Research and Treatment | Issue 2/2014

Login to get access

Abstract

We investigated the expression of –CXC chemokine ligand 13 (CXCL13) and its receptor –CXC chemokine receptor 5 (CXCR5) in 98 breast cancer (BC) patients with infiltrating duct carcinoma, out of which 56 were found lymph node metastasis (LNM) positive. Interestingly, co-expression of CXCL13 and CXCR5 showed a significant correlation with LNM. Since, epithelial to mesenchymal transition (EMT) is highly associated with metastasis we investigated EMT-inducing potential of CXCL13 in BC cell lines. In CXCL13-stimulated BC cells, expression of various mesenchymal markers (Vimentin, N-cadherin), EMT regulators (Snail, Slug), and matrix metalloproteinase-9 (MMP9) was increased, whereas the expression of epithelial marker E-cadherin was found to be decreased. In addition, expression of receptor activator of nuclear factor kappa-B ligand (RANKL), which is known to regulate MMP9 expression via Src activation, was also significantly increased after CXCL13 stimulation. Using specific protein kinase inhibitors, we confirmed that CXCL13 stimulated EMT and MMP9 expression via RANKL–Src axis in BC cell lines. To further validate this observation, we examined gene expression patterns in primary breast tumors and detected significantly higher expression of various mesenchymal markers and regulators in CXCL13–CXCR5 co-expressing patients. Therefore, this study showed the EMT-inducing potential of CXCL13 as well as demonstrated the prognostic value of CXCL13–CXCR5 co-expression in primary BC. Moreover, CXCL13–CXCR5–RANKL–Src axis may present a therapeutic target in LNM positive BC patients.
Appendix
Available only for authorised users
Literature
1.
2.
Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM (1998) Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem 273:4282–4287CrossRefPubMed
3.
Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121–127CrossRefPubMed
4.
Patel J, Channon KM, McNeill E (2013) The downstream regulation of chemokine receptor signaling: implications for atherosclerosis. Mediators Inflamm. doi:10.​1155/​2013/​459520
5.
Latek D, Modzelewska A, Trzaskowski B, Palczewski K, Filipek S (2012) G protein-coupled receptors-recent advances. Acta Biochim Pol 59:515–529PubMedCentralPubMed
6.
Zlontik A (2004) Chemokines in neoplastic progression. Semin Cancer Biol 14:181–185CrossRef
7.
Longo-Imedio MI, Longo N, Trevino I, Lazaro P, Sanchez-Mateos P (2005) Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 117:861–865CrossRefPubMed
8.
Murphy C, McGurk M, Pettigrew J et al (2005) Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11:4117–4127CrossRefPubMed
9.
10.
Belperio JA, Keane MP, Arenberg DA et al (2000) CXC chemokines in angiogenesis. J Leukoc Biol 68:1–8PubMed
11.
12.
Murakami T, Cardones AR, Hwang ST (2004) Chemokine receptors and melanoma metastasis. J Dermatol Sci 36:71–78CrossRefPubMed
13.
Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M (2005) Chemokines in tumor progression and metastasis. Cancer Sci 96:317–322CrossRefPubMed
14.
Shayan R, Achen MG, Stacker SA (2006) Lymphatic vessels in cancer metastasis: bridging the gaps. Carcinogenesis 27:1729–1738CrossRefPubMed
15.
Li YM, Pan Y, Wei Y et al (2004) Up-regulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6:459–469CrossRefPubMed
16.
Bachelder RE, Wendt MA, Mercurio AM (2002) Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62:7203–7206PubMed
17.
Muller A, Homey B, Soto H et al (2001) Involvement of chemokine receptors in breast cancer. Nature 410:50–56CrossRefPubMed
18.
19.
Kim M, Koh YJ, Kim KE et al (2010) CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 70:10411–10421CrossRefPubMed
20.
Rhodes LV, Short SP, Neel NF et al (2011) Chemokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 71:603–613PubMedCentralCrossRefPubMed
21.
22.
Zhou Y, Zhang J, Liu Q et al (2005) The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells. Carcinogenesis 26:2058–2068CrossRefPubMed
23.
24.
Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, Huang RP (2004) Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 109:507–515CrossRefPubMed
25.
Meijer J, Zeelenberg IS, Sipos B, Roos E (2006) The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res 66:9576–9582CrossRefPubMed
26.
Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA (2007) Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 110:3316–3325CrossRefPubMed
27.
Panse J, Friedrichs K, Marx A et al (2008) Chemokine CXCL13 is overexpressed in the tumor tissue and in the peripheral blood of breast cancer patients. Br J Cancer 99:930–938PubMedCentralCrossRefPubMed
28.
Airoldi I, Cocco C, Morandi F, Prigione I, Pistoia V (2008) CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immunother 57:541–548CrossRefPubMed
29.
Razmkhah M, Jaberipour M, Safaei A, Talei AR, Erfani N, Ghaderi A (2012) Chemokine and chemokine receptors: a comparative study between metastatic and non-metastatic lymph nodes in breast cancer patients. Eur Cytokine Netw 23:72–77PubMed
30.
El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S, Lillard JW Jr (2010) PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer 9:85PubMedCentralCrossRefPubMed
31.
Guarino M (2007) Epithelial-mesenchymal transition and tumor invasion. Int J Biochem Cell Biol 39:2153–2160CrossRefPubMed
32.
Markiewicz A, Ahrends T, Wełnicka-Jaskiewicz M et al (2012) Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med 10:226PubMedCentralCrossRefPubMed
33.
Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131–142CrossRefPubMed
34.
Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4:118–132CrossRefPubMed
35.
Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890CrossRefPubMed
36.
Fata JE, Kong YY, Li J et al (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103:41–50CrossRefPubMed
37.
Zhang L, Teng Y, Zhang Y et al (2012) C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway. Oncol Lett 3:395–400PubMedCentralPubMed
38.
Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC (2008) RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastatic genes. Prostate 68:92–104CrossRefPubMed
39.
Neve RM, Chin K, Fridlyand J et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515–527PubMedCentralCrossRefPubMed
40.
41.
Weigelt B, Peterse JL, van’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602CrossRefPubMed
42.
Sen U, Sankaranarayanan R, Mandal S, Ramanakumar AV, Parkin DM, Siddiqi M (2002) Cancer patterns in eastern India: the first report of the Kolkata cancer registry. Int J Cancer 100:86–91CrossRefPubMed
43.
44.
Singh S, Singh R, Singh UP et al (2009) Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer 125:2288–2295PubMedCentralCrossRefPubMed
45.
Singh S, Singh R, Sharma PK et al (2009) Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett 283:29–35PubMedCentralCrossRefPubMed
46.
Del Grosso F, Coco S, Scaruffi P et al (2011) Role of CXCL13–CXCR5 crosstalk between malignant neuroblastoma cells and Schwannian stromal cells in neuroblastic tumors. Mol Cancer Res 9:815–823CrossRefPubMed
47.
Ebisuno Y, Tanaka T, Kanemitsu N et al (2003) Cutting edge: the B cell chemokine CXC chemokine ligand 13/B lymphocyte chemoattractant is expressed in the high endothelial venules of lymph nodes and Peyer’s patches and affects B cell trafficking across high endothelial venules. J Immunol 171:1642–1646CrossRefPubMed
48.
Peinado H, Portillo F, Cano A (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48:365–375CrossRefPubMed
49.
Dong C, Wu Y, Yao J et al (2012) G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest 122:1469–1486PubMedCentralCrossRefPubMed
50.
Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA (2003) MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113:207–219CrossRefPubMed
51.
El-Haibi CP, Singh R, Gupta P, Sharma PK, Greenleaf KN, Singh S, Lillard JW Jr (2012) Antibody microarray analysis of signaling networks regulated by Cxcl13 and Cxcr5 in prostate cancer. J Proteomics Bioinform 5:177–184PubMedCentralCrossRefPubMed
52.
Zhao Y, Li X, Sun X, Zhang Y, Ren H (2012) EMT phenotype is induced by increased Src kinase activity via Src-mediated caspase-8 phosphorylation. Cell Physiol Biochem 29:341–352CrossRefPubMed
Metadata
Title
CXCL13–CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis
Authors
Subir Biswas
Suman Sengupta
Sougata Roy Chowdhury
Samir Jana
Gunjan Mandal
Palash Kumar Mandal
Nipun Saha
Vivek Malhotra
Arnab Gupta
Dmitry V. Kuprash
Arindam Bhattacharyya
Publication date
01-01-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2811-8

Other articles of this Issue 2/2014

Breast Cancer Research and Treatment 2/2014 Go to the issue

Brief Report

Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women

Epidemiology

Prospective associations of depression with survival: a population-based cohort study in patients with newly diagnosed breast cancer

Preclinical Study

Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin

Editorial

What is the future of magnetic nanoparticles in the axillary management of breast cancer?

Clinical trial

A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102

Epidemiology

Breast cancer screening of women aged 70–74 years: results from a natural experiment across Australia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits